Results 41 to 50 of about 52,122 (312)
Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon
Background Opioid agonist therapy has been widely used to reduce harms among individuals with opioid use disorder but its effectiveness has not been evaluated in the Middle East North African (MENA) region.
Ali Ghaddar, Zeinab Abbas, Ramzi Haddad
doaj +1 more source
Opioid agonist treatment for pharmaceutical opioid dependent people
There are increasing concerns regarding pharmaceutical opioid harms including overdose and dependence, with an associated increase in treatment demand. People dependent on pharmaceutical opioids appear to differ in important ways from people who use heroin, yet most opioid agonist treatment research has been conducted in people who use heroin.To assess
Nielsen, S +5 more
openaire +3 more sources
This study explores the opposing effects of the mGluR2 and mGluR3 receptors on amyloid precursor protein processing. mGluR2 promotes amyloidogenic cleavage, while mGluR3 favors non‐amyloidogenic pathways. Using a brain‐penetrant nanobody as a mGluR2 positive allosteric modulator, the study uncovers how its chronic activation aggravates amyloid‐β burden
Pierre‐André Lafon +21 more
wiley +1 more source
Freedom from thirst is an undeniable requirement of the poultry industry. However, the regulatory mechanisms underlying water intake in chicks are not yet fully understood.
Yuhui Zhang +4 more
doaj +1 more source
Functional activity of the cannabinoid 1 receptor is not affected by opioid antagonists in the rat brain [PDF]
BackgroundWIN55212-2 is a synthetic cannabinoid agonist and selective to cannabinoid 1 (CB1) receptors, which are distributed mainly in the central nervous system.
Heeseung Lee
doaj +1 more source
Model figure of BBBECs TfR1 regulation in control and RLS: Graphical representation of TfR1 regulation in ECs by IRPs and representing it can be dysregulated by miR‐124‐3p in ECs of RLS. FPN1, ferroportin; BBBEC, blood‐brain barrier endothelial cells; IRP, iron regulatory proytein1/2; TfR1, Transferrin receptor; IRE, Iron responsive elements; Tf ...
Kondaiah Palsa +6 more
wiley +1 more source
Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and pharmacokinetic properties that may be preferable to those of Schedule II full μ-opioid receptor agonists.
Jeffrey Gudin, Jeffrey Fudin
doaj +1 more source
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig +7 more
wiley +1 more source
ObjectiveThe objective of this study was to evaluate the relationship between concurrent physician-based mental health services, all-cause mortality, and acute health service use for individuals enrolled in Opioid Agonist Treatment in Ontario, Canada ...
Kristen A Morin +6 more
doaj +1 more source
Comportamento de coçar e nocicepção evidenciados após a aplicação facial de endotelina-1: um novo teste, uma nova oportunidade farmacológica [PDF]
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Farmacologia, Florianópolis, 2011O presente trabalho reproduziu o modelo experimental descrito por Shimada e Lamotte, (2008), e o
Gomes, Lenyta Oliveira
core

